SPARC

Sun Pharma Advanced Research Company Share Price

₹201.48 +1.7 (0.85%)

28 Dec, 2024 00:56

SIP TrendupStart SIP in SPARC

Start SIP

Performance

  • Low
  • ₹200
  • High
  • ₹204
  • 52 Week Low
  • ₹190
  • 52 Week High
  • ₹473
  • Open Price₹201
  • Previous Close₹200
  • Volume691,243

Investment Returns

  • Over 1 Month -4.71%
  • Over 3 Month -5.26%
  • Over 6 Month -18.64%
  • Over 1 Year -22.07%
SIP Lightning

Smart Investing Starts Here Start SIP with Sun Pharma Advanced Research Company for Steady Growth!

Invest Now

Sun Pharma Advanced Research Company Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -16
  • PEG Ratio
  • -
  • Market Cap Cr
  • 6,539
  • P/B Ratio
  • 52
  • Average True Range
  • 8.21
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.46
  • RSI
  • 41.37
  • MFI
  • 73.58

Sun Pharma Advanced Research Company Financials

Sun Pharma Advanced Research Company Technicals

EMA & SMA

Current Price
₹201.48
+ 1.7 (0.85%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹210.19
  • 50 Day
  • ₹211.66
  • 100 Day
  • ₹218.45
  • 200 Day
  • ₹233.56

Resistance and Support

201.66 Pivot Speed
  • R3 208.32
  • R2 206.16
  • R1 203.82
  • S1 199.32
  • S2 197.16
  • S3 194.82

What's your outlook on Sun Pharma Advanced Research Company?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sun Pharma Advanced Research Company Ltd. (SPARC) focuses on developing innovative pharmaceutical products, including novel drug delivery systems and new chemical entities. It drives research in therapeutic areas like oncology, dermatology, and neurology to address unmet medical needs.

Sun Pharma Advd.Resh. has an operating revenue of Rs. 60.09 Cr. on a trailing 12-month basis. An annual revenue de-growth of -58% needs improvement, Pre-tax margin of -512% needs improvement, ROE of -307% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 15 which is a POOR score indicating inconsistency in earnings, a RS Rating of 8 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 61 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sun Pharma Advanced Research Company Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-04 Quarterly Results
2024-08-05 Quarterly Results
2024-05-24 Audited Results
2024-02-05 Quarterly Results
2023-11-06 Quarterly Results

Sun Pharma Advanced Research Company F&O

Sun Pharma Advanced Research Company Shareholding Pattern

65.67%
0.1%
0%
2.15%
0%
19.2%
12.88%

About Sun Pharma Advanced Research Company

  • NSE Symbol
  • SPARC
  • BSE Symbol
  • 532872
  • ISIN
  • INE232I01014

Similar Stocks to Sun Pharma Advanced Research Company

Sun Pharma Advanced Research Company FAQs

Sun Pharma Advanced Research Company share price is ₹201 As on 28 December, 2024 | 00:42

The Market Cap of Sun Pharma Advanced Research Company is ₹6538.5 Cr As on 28 December, 2024 | 00:42

The P/E ratio of Sun Pharma Advanced Research Company is -16 As on 28 December, 2024 | 00:42

The PB ratio of Sun Pharma Advanced Research Company is 52 As on 28 December, 2024 | 00:42

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23